Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Novartis unveils new Phase III data advancing kidney disease treatments at ERA 2026.

Market News
26 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Novartis announced it will present 15 abstracts at the European Renal Association Congress 2026, highlighting late-stage clinical data for kidney disease treatments including Vanrafia (atrasentan), Fabhalta (iptacopan), and zigakibart for IgA nephropathy (IgAN). These findings demonstrate Novartis' commitment to advancing scientific understanding and treatment options for progressive immune-mediated kidney diseases, aiming to improve patient outcomes and delay dialysis or transplantation. The data presentations include long-term efficacy and safety results, as well as insights into disease characteristics that will inform future research and care strategies.

More News (NVS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App